MX2019012431A - Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. - Google Patents
Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.Info
- Publication number
- MX2019012431A MX2019012431A MX2019012431A MX2019012431A MX2019012431A MX 2019012431 A MX2019012431 A MX 2019012431A MX 2019012431 A MX2019012431 A MX 2019012431A MX 2019012431 A MX2019012431 A MX 2019012431A MX 2019012431 A MX2019012431 A MX 2019012431A
- Authority
- MX
- Mexico
- Prior art keywords
- ahr inhibitors
- indole
- inhibitors
- indole ahr
- ahr
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488476P | 2017-04-21 | 2017-04-21 | |
| US201762592542P | 2017-11-30 | 2017-11-30 | |
| US201862658454P | 2018-04-16 | 2018-04-16 | |
| PCT/US2018/028532 WO2018195397A2 (en) | 2017-04-21 | 2018-04-20 | Indole ahr inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019012431A true MX2019012431A (es) | 2020-08-03 |
Family
ID=63856153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012431A MX2019012431A (es) | 2017-04-21 | 2018-04-20 | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10570138B2 (https=) |
| EP (2) | EP3612030B1 (https=) |
| JP (2) | JP7232244B2 (https=) |
| KR (1) | KR102668371B1 (https=) |
| CN (1) | CN110831600B (https=) |
| AU (1) | AU2018256459B2 (https=) |
| CA (1) | CA3059939A1 (https=) |
| CL (1) | CL2019003015A1 (https=) |
| CO (1) | CO2019011584A2 (https=) |
| ES (1) | ES3064664T3 (https=) |
| FI (1) | FI3612030T3 (https=) |
| IL (1) | IL270025B2 (https=) |
| MX (1) | MX2019012431A (https=) |
| NZ (1) | NZ758243A (https=) |
| PT (1) | PT3612030T (https=) |
| SG (1) | SG11201909710XA (https=) |
| TW (1) | TWI778050B (https=) |
| WO (1) | WO2018195397A2 (https=) |
| ZA (1) | ZA201906822B (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7291077B2 (ja) | 2016-12-16 | 2023-06-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｊａｋファミリーのキナーゼの低分子阻害物質 |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| TW201841916A (zh) * | 2017-04-12 | 2018-12-01 | 美商麥珍塔治療學股份有限公司 | 芳香烴受體拮抗劑及其用途 |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| FR3066761B1 (fr) * | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
| BR112020003116A2 (pt) | 2017-08-17 | 2020-08-04 | Ikena Oncology, Inc. | inibidores de ahr e usos dos mesmos |
| WO2019156989A1 (en) * | 2018-02-06 | 2019-08-15 | Ideaya Biosciences, Inc. | COMPOUNDS AND METHODS FOR THE MODULATION OF AhR |
| JP7382348B2 (ja) | 2018-02-06 | 2023-11-16 | アイディアヤ バイオサイエンシーズ，インコーポレイティド | ＡｈＲモジュレータ |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| WO2020050409A1 (en) * | 2018-09-07 | 2020-03-12 | Otsuka Pharmaceutical Co., Ltd. | Heterocyclic compound |
| EP3867253A4 (en) * | 2018-10-16 | 2022-05-18 | Ikena Oncology, Inc. | Indole ahr inhibitors and uses thereof |
| CN113301897A (zh) * | 2018-10-17 | 2021-08-24 | 美真达治疗公司 | 用芳烃受体拮抗剂治疗癌症的方法 |
| JP2022511457A (ja) * | 2018-11-30 | 2022-01-31 | セルラリティ インク． | 造血幹細胞および前駆細胞の活性化に使用するための芳香族化合物 |
| AU2019387491A1 (en) * | 2018-11-30 | 2021-05-27 | Celularity Inc. | Expansion of natural killer cells and ILC3 cells with novel aromatic compounds |
| CN109813913B (zh) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | 芳烃受体(AhR)在预测免疫治疗效果中的应用 |
| CA3128521A1 (en) | 2019-02-27 | 2020-09-03 | Millennium Pharmaceuticals, Inc. | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors |
| US12473262B2 (en) * | 2019-07-30 | 2025-11-18 | Oregon State University | Aryl hydrocarbon receptor activators |
| AU2020386967A1 (en) * | 2019-11-22 | 2022-07-07 | Sail Biomedicines, Inc. | Pyridopyrimidinone derivatives as AHR antagonists |
| BR112022009856A2 (pt) * | 2019-11-26 | 2022-08-02 | Hoffmann La Roche | Compostos de 1,8-naftiridin-2-ona para o tratamento de doença autoimune |
| EP4065090A1 (en) * | 2019-11-26 | 2022-10-05 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| AU2020394424A1 (en) * | 2019-11-26 | 2022-06-16 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| TW202146416A (zh) | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| CA3167283A1 (en) | 2020-01-10 | 2021-07-15 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| JP2023515128A (ja) | 2020-02-26 | 2023-04-12 | ジャガー セラピューティクス ピーティーイーリミテッド | Ａｈｒシグナル伝達の調節に有用なピリドピリミジン誘導体 |
| CN115397818A (zh) * | 2020-03-27 | 2022-11-25 | 东亚St株式会社 | 氨基嘧啶衍生物及其作为芳烃受体调节剂的应用 |
| US12570638B2 (en) | 2020-05-20 | 2026-03-10 | Sail Biomedicines, Inc. | Fused imidazole derivatives as AHR antagonists |
| US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| WO2022029063A1 (en) * | 2020-08-04 | 2022-02-10 | Bayer Aktiengesellschaft | Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines |
| CN114369097B (zh) * | 2020-10-15 | 2023-07-14 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| MX2023004847A (es) * | 2020-10-28 | 2023-07-11 | Ikena Oncology Inc | Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina. |
| CN114644627B (zh) * | 2020-12-18 | 2024-06-11 | 山东轩竹医药科技有限公司 | AhR抑制剂及其用途 |
| CN112656789A (zh) * | 2020-12-31 | 2021-04-16 | 中国科学院生态环境研究中心 | Ficz在抑制肿瘤细胞迁移中的应用 |
| CN114805361B (zh) * | 2021-01-17 | 2024-02-20 | 上海凌达生物医药有限公司 | 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途 |
| MX2023010642A (es) | 2021-03-11 | 2023-11-28 | Janssen Pharmaceutica Nv | Lorpucitinib para uso en el tratamiento de trastornos mediados por jak. |
| WO2023020512A1 (zh) * | 2021-08-16 | 2023-02-23 | 成都奥睿药业有限公司 | 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途 |
| WO2023033742A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| WO2023033741A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| CN118076613A (zh) * | 2021-09-02 | 2024-05-24 | 捷豹治疗有限公司 | 可用于调节AhR信号传导的化合物 |
| CN115093400B (zh) * | 2021-09-18 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂及其用途和制备方法 |
| WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN115925684B (zh) * | 2021-12-03 | 2025-02-28 | 徐诺药业(南京)有限公司 | 一种嘧啶类衍生物及其制备方法和应用 |
| CN118541372A (zh) | 2022-01-11 | 2024-08-23 | 德国癌症研究中心 | 用于治疗癌症的双环三嗪衍生物 |
| IL315733A (en) | 2022-04-08 | 2024-11-01 | SHY Therapeutics LLC | Compounds that Interact with RAS Superfamily Proteins for the Treatment of Cancer, Inflammatory, Basoplastic, and Fibrotic Diseases |
| CN117624168A (zh) * | 2022-08-19 | 2024-03-01 | 德明药泰生物技术（深圳）有限公司 | 稠环杂环类化合物及其制备方法和应用 |
| CN115850329A (zh) * | 2022-09-16 | 2023-03-28 | 东莞市均成高新材料有限公司 | 环三联芳膦、它们的制备方法及用途 |
| CN119948035A (zh) | 2022-10-03 | 2025-05-06 | 捷豹治疗有限公司 | 可用于调节AhR信号传导的化合物 |
| CN115804776A (zh) * | 2022-12-16 | 2023-03-17 | 国纳之星(上海)纳米科技发展有限公司 | 一种芳香烃受体抑制剂和5-氟尿嘧啶合用在治疗抑制肿瘤药物中的应用 |
| CN116482278B (zh) * | 2023-05-06 | 2024-02-09 | 广州清瑞生物科技有限责任公司 | 一种用于检测阿昔洛韦的对照品的制备方法 |
| TW202510855A (zh) * | 2023-08-18 | 2025-03-16 | 美商英塞特公司 | 作為ｍｒｇｐｒｘ２拮抗劑之雙環雜環化合物 |
| EP4512806A1 (en) | 2023-08-25 | 2025-02-26 | Mablink Bioscience | Molecular glue degraders and uses thereof |
| EP4512427A1 (en) | 2023-08-25 | 2025-02-26 | Mablink Bioscience | Antibody-drug conjugates based on molecular glue degraders and uses thereof |
| CN117229284B (zh) * | 2023-11-10 | 2024-02-06 | 上海泽德曼医药科技有限公司 | 三环稠杂环类化合物、其制备方法及其在医药上的应用 |
| WO2025114771A1 (en) | 2023-11-29 | 2025-06-05 | Latvian Institute Of Organic Synthesis | A new class of aryl hydrocarbon receptor antagonists and their optimisation |
| WO2025254418A1 (ko) * | 2024-06-03 | 2025-12-11 | 동아에스티 주식회사 | 아미노피리미딘 유도체의 결정다형 및 이의 제조방법 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721356A (en) | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| HU229024B1 (en) * | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof |
| US5962473A (en) | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| EP1343506A1 (de) * | 2000-12-19 | 2003-09-17 | MERCK PATENT GmbH | Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate |
| EP2168576A3 (en) * | 2001-09-14 | 2010-05-26 | Shionogi & Co., Ltd. | Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases |
| ES2285164T3 (es) * | 2002-09-04 | 2007-11-16 | Schering Corporation | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina. |
| MY133311A (en) * | 2002-09-19 | 2007-11-30 | Schering Corp | Novel imidazopyridines as cyclin dependent kinase inhibitors |
| JP4895806B2 (ja) | 2003-04-09 | 2012-03-14 | エクセリクシス， インク． | Ｔｉｅ−２モジュレータと使用方法 |
| AR047969A1 (es) | 2004-02-25 | 2006-03-15 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JP2008520749A (ja) | 2004-11-23 | 2008-06-19 | レディ ユーエス セラピューティックス， インコーポレイテッド | 新規二環式ヘテロ環化合物、その調製のためのプロセス、およびその新規二環式ヘテロ環化合物を含む組成物 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008058126A2 (en) * | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| JP5643105B2 (ja) * | 2007-12-14 | 2014-12-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体 |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| JP5802676B2 (ja) | 2009-12-04 | 2015-10-28 | センワ バイオサイエンシズ インコーポレイテッド | Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物 |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| WO2012044562A2 (en) * | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde10 inhibitors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| AP2013007253A0 (en) * | 2011-04-21 | 2013-11-30 | Origenis Gmbh | Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| EP2788476B1 (en) * | 2011-12-08 | 2019-05-22 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| AR090650A1 (es) * | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014060112A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| WO2014138485A1 (en) * | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| CN108290855A (zh) | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途 |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| TW201841916A (zh) | 2017-04-12 | 2018-12-01 | 美商麥珍塔治療學股份有限公司 | 芳香烴受體拮抗劑及其用途 |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| EP3867253A4 (en) | 2018-10-16 | 2022-05-18 | Ikena Oncology, Inc. | Indole ahr inhibitors and uses thereof |
| AU2020394424A1 (en) | 2019-11-26 | 2022-06-16 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| EP4065090A1 (en) | 2019-11-26 | 2022-10-05 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| CA3167283A1 (en) | 2020-01-10 | 2021-07-15 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| MX2023004847A (es) | 2020-10-28 | 2023-07-11 | Ikena Oncology Inc | Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina. |
-
2018
- 2018-04-20 MX MX2019012431A patent/MX2019012431A/es unknown
- 2018-04-20 AU AU2018256459A patent/AU2018256459B2/en active Active
- 2018-04-20 PT PT187874144T patent/PT3612030T/pt unknown
- 2018-04-20 CA CA3059939A patent/CA3059939A1/en active Pending
- 2018-04-20 TW TW107113564A patent/TWI778050B/zh active
- 2018-04-20 KR KR1020197034489A patent/KR102668371B1/ko active Active
- 2018-04-20 US US15/958,586 patent/US10570138B2/en active Active
- 2018-04-20 NZ NZ758243A patent/NZ758243A/en unknown
- 2018-04-20 ES ES18787414T patent/ES3064664T3/es active Active
- 2018-04-20 EP EP18787414.4A patent/EP3612030B1/en active Active
- 2018-04-20 JP JP2020507495A patent/JP7232244B2/ja active Active
- 2018-04-20 WO PCT/US2018/028532 patent/WO2018195397A2/en not_active Ceased
- 2018-04-20 EP EP25224138.5A patent/EP4710923A2/en active Pending
- 2018-04-20 FI FIEP18787414.4T patent/FI3612030T3/fi active
- 2018-04-20 SG SG11201909710X patent/SG11201909710XA/en unknown
- 2018-04-20 CN CN201880038301.XA patent/CN110831600B/zh active Active
-
2019
- 2019-10-16 ZA ZA2019/06822A patent/ZA201906822B/en unknown
- 2019-10-17 IL IL270025A patent/IL270025B2/en unknown
- 2019-10-18 CO CONC2019/0011584A patent/CO2019011584A2/es unknown
- 2019-10-21 CL CL2019003015A patent/CL2019003015A1/es unknown
- 2019-10-30 US US16/668,070 patent/US10689388B1/en active Active
-
2020
- 2020-04-08 US US16/843,606 patent/US11358969B2/en active Active
-
2022
- 2022-05-06 US US17/662,246 patent/US12077542B2/en active Active
- 2022-06-06 JP JP2022091740A patent/JP2022116319A/ja not_active Withdrawn
-
2024
- 2024-07-12 US US18/771,297 patent/US20250122205A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201906822B (en) | Indole ahr inhibitors and uses thereof | |
| MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| WO2020243415A3 (en) | Tead inhibitors and uses thereof | |
| PH12021553018A1 (en) | New egfr inhibitors | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| MX2020006812A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| PH12022551522A1 (en) | Smarca degraders and uses thereof | |
| MY205416A (en) | Tyk2 inhibitors and uses thereof | |
| MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
| MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
| MX2018005292A (es) | Inhibidores de acc y usos de los mismos. | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
| MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| PH12018500409A1 (en) | New bicyclic compounds as dual atx/ca inhibitors | |
| MX2018006288A (es) | Inhibidores de acc tipo ester y usos de los mismos. | |
| EA201691916A1 (ru) | Биарильные ингибиторы киназы |